These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 20139039)

  • 1. Growth restriction of an experimental live attenuated human parainfluenza virus type 2 vaccine in human ciliated airway epithelium in vitro parallels attenuation in African green monkeys.
    Schaap-Nutt A; Scull MA; Schmidt AC; Murphy BR; Pickles RJ
    Vaccine; 2010 Mar; 28(15):2788-98. PubMed ID: 20139039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of interferon in the replication of human parainfluenza virus type 1 wild type and mutant viruses in human ciliated airway epithelium.
    Bartlett EJ; Hennessey M; Skiadopoulos MH; Schmidt AC; Collins PL; Murphy BR; Pickles RJ
    J Virol; 2008 Aug; 82(16):8059-70. PubMed ID: 18524813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human parainfluenza virus type 2 V protein inhibits interferon production and signaling and is required for replication in non-human primates.
    Schaap-Nutt A; D'Angelo C; Scull MA; Amaro-Carambot E; Nishio M; Pickles RJ; Collins PL; Murphy BR; Schmidt AC
    Virology; 2010 Feb; 397(2):285-98. PubMed ID: 19969320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3' genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primates.
    Nolan SM; Skiadopoulos MH; Bradley K; Kim OS; Bier S; Amaro-Carambot E; Surman SR; Davis S; St Claire M; Elkins R; Collins PL; Murphy BR; Schaap-Nutt A
    Vaccine; 2007 Aug; 25(34):6409-22. PubMed ID: 17658669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cold-passaged human parainfluenza type 3 viruses contain ts and non-ts mutations leading to attenuation in rhesus monkeys.
    Hall SL; Stokes A; Tierney EL; London WT; Belshe RB; Newman FC; Murphy BR
    Virus Res; 1992 Mar; 22(3):173-84. PubMed ID: 1320790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a Live-Attenuated Human Parainfluenza Virus Type 2 Vaccine in Adults and Children.
    Karron RA; Herbert K; Wanionek K; Schmidt AC; Schaap-Nutt A; Collins PL; Buchholz UJ
    J Pediatric Infect Dis Soc; 2023 Apr; 12(3):173-176. PubMed ID: 36594442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Replacement of the ectodomains of the hemagglutinin-neuraminidase and fusion glycoproteins of recombinant parainfluenza virus type 3 (PIV3) with their counterparts from PIV2 yields attenuated PIV2 vaccine candidates.
    Tao T; Skiadopoulos MH; Davoodi F; Riggs JM; Collins PL; Murphy BR
    J Virol; 2000 Jul; 74(14):6448-58. PubMed ID: 10864657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3.
    Tao T; Davoodi F; Cho CJ; Skiadopoulos MH; Durbin AP; Collins PL; Murphy BR
    Vaccine; 2000 Jan; 18(14):1359-66. PubMed ID: 10618533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of mutations in human parainfluenza viruses during passage in primary human bronchial/tracheal epithelial air-liquid interface cultures and cell lines.
    Sugimoto S; Kawase M; Suwa R; Kume Y; Chishiki M; Ono T; Okabe H; Norito S; Hanaki K-I; Hosoya M; Hashimoto K; Shirato K
    Microbiol Spectr; 2024 Sep; 12(9):e0116424. PubMed ID: 39078148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced growth of influenza A virus by coinfection with human parainfluenza virus type 2.
    Goto H; Ihira H; Morishita K; Tsuchiya M; Ohta K; Yumine N; Tsurudome M; Nishio M
    Med Microbiol Immunol; 2016 Jun; 205(3):209-18. PubMed ID: 26582554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The recombinant chimeric human parainfluenza virus type 1 vaccine candidate, rHPIV3-1cp45, is attenuated, immunogenic, and protective in African green monkeys.
    Skiadopoulos MH; Tatem JM; Surman SR; Mitcho Y; Wu SL; Elkins WR; Murphy BR
    Vaccine; 2002 Mar; 20(13-14):1846-52. PubMed ID: 11906774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attenuation and efficacy of human parainfluenza virus type 1 (HPIV1) vaccine candidates containing stabilized mutations in the P/C and L genes.
    Bartlett EJ; Castaño A; Surman SR; Collins PL; Skiadopoulos MH; Murphy BR
    Virol J; 2007 Jul; 4():67. PubMed ID: 17605811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human parainfluenza virus type 2 with mutations in V that permit cellular interferon signaling are not attenuated in non-human primates.
    Schaap-Nutt A; D'Angelo C; Amaro-Carambot E; Nolan SM; Davis S; Wise SM; Higgins C; Bradley K; Kim O; Mayor R; Skiadopoulos MH; Collins PL; Murphy BR; Schmidt AC
    Virology; 2010 Oct; 406(1):65-79. PubMed ID: 20667570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attenuation of the recombinant human parainfluenza virus type 3 cp45 candidate vaccine virus is augmented by importation of the respiratory syncytial virus cpts530 L polymerase mutation.
    Skiadopoulos MH; Surman SR; St Claire M; Elkins WR; Collins PL; Murphy BR
    Virology; 1999 Jul; 260(1):125-35. PubMed ID: 10405364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Replacement of the F and G proteins of respiratory syncytial virus (RSV) subgroup A with those of subgroup B generates chimeric live attenuated RSV subgroup B vaccine candidates.
    Whitehead SS; Hill MG; Firestone CY; St Claire M; Elkins WR; Murphy BR; Collins PL
    J Virol; 1999 Dec; 73(12):9773-80. PubMed ID: 10559287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sendai virus, a murine parainfluenza virus type 1, replicates to a level similar to human PIV1 in the upper and lower respiratory tract of African green monkeys and chimpanzees.
    Skiadopoulos MH; Surman SR; Riggs JM; Elkins WR; St Claire M; Nishio M; Garcin D; Kolakofsky D; Collins PL; Murphy BR
    Virology; 2002 May; 297(1):153-60. PubMed ID: 12083845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses.
    Newman JT; Riggs JM; Surman SR; McAuliffe JM; Mulaikal TA; Collins PL; Murphy BR; Skiadopoulos MH
    J Virol; 2004 Feb; 78(4):2017-28. PubMed ID: 14747566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth of respiratory syncytial virus in primary epithelial cells from the human respiratory tract.
    Wright PF; Ikizler MR; Gonzales RA; Carroll KN; Johnson JE; Werkhaven JA
    J Virol; 2005 Jul; 79(13):8651-4. PubMed ID: 15956607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. African green monkeys provide a useful nonhuman primate model for the study of human parainfluenza virus types-1, -2, and -3 infection.
    Durbin AP; Elkins WR; Murphy BR
    Vaccine; 2000 May; 18(22):2462-9. PubMed ID: 10738104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes.
    Skiadopoulos MH; Durbin AP; Tatem JM; Wu SL; Paschalis M; Tao T; Collins PL; Murphy BR
    J Virol; 1998 Mar; 72(3):1762-8. PubMed ID: 9499025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.